Medicare Enrolled
Dr. Janet Chin, MD
Hematology & Oncology · Lisle, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Chin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Chin
Dr. Janet Chin is a hematology & oncology specialist in Lisle, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Chin performed 60,545 Medicare services across 2,377 unique beneficiaries.
Between the years covered by Open Payments, Dr. Chin received a total of $3,123 from 15 pharmaceutical and/or device companies across 43 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Chin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 18% volume in IL
$3,123 industry payments
Medicare Practice Summary
Medicare Utilization ↗60,545
Medicare services
Top 18% in IL for hematology & oncology
2,377
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,027 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
17,340 | $0 | $3 |
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
16,200 | $17 | $33 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
10,200 | $0 | $3 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
4,650 | $34 | $81 |
| Denosumab injection (Prolia/Xgeva) | 3,240 | $18 | $27 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
2,170 | $27 | $149 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
954 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 690 | $1 | $142 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
621 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
525 | $8 | $40 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
468 | $109 | $740 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
383 | $10 | $55 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
283 | $13 | $54 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
283 | $57 | $157 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
282 | $48 | $201 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
243 | $105 | $380 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
241 | $96 | $229 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
179 | $7 | $416 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
172 | $11 | $62 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
146 | $23 | $95 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
104 | $1 | $3 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
93 | $6 | $30 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
90 | $24 | $95 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
79 | $13 | $70 |
| Iron level test | 71 | $6 | $33 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
71 | $8 | $45 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
50 | $46 | $167 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
49 | $65 | $157 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
47 | $108 | $354 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
45 | $70 | $235 |
| Folic acid level test A blood test that measures the amount of folic acid in the serum. |
44 | $14 | $77 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
44 | $54 | $189 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
44 | $4 | $15 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
43 | $6 | $33 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
43 | $16 | $70 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
42 | $14 | $77 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
41 | $4 | $18 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
40 | $98 | $223 |
| Automated red blood cell count An automated laboratory test that measures the number of red blood cells in a blood sample. |
34 | $4 | $21 |
| New patient office visit, complex (60-74 min) | 32 | $152 | $809 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
28 | $115 | $359 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
28 | $119 | $582 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
24 | $19 | $97 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
22 | $19 | $67 |
| Blood creatinine level test A blood test that measures the amount of creatinine, a waste product from muscle wear and tear, to help assess kidney function. |
21 | $5 | $26 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
17 | $16 | $86 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
17 | $124 | $573 |
| Blood urea nitrogen test A blood test that measures the amount of urea nitrogen to assess kidney function. |
12 | $4 | $20 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
67.8% high complexity
27.3% medium
4.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,123
Total received (2018-2024)
Avg $520/year across 6 years
Top 50% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
15
Companies
43
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,882 (60.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,241 (39.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,428
2023
$192
2022
$267
2021
$184
2019
$40
2018
$12
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Deciphera Pharmaceuticals Inc.
$1,882
AstraZeneca Pharmaceuticals LP
$255
STERIS CORPORATION
$245
ABBVIE INC.
$30
Gilead Sciences, Inc.
$17
Top 3 companies account for 98.0% of 2024 payments
All-time payments by company (2018-2024) ›
Deciphera Pharmaceuticals Inc.
$1,882
AstraZeneca Pharmaceuticals LP
$255
STERIS CORPORATION
$245
PFIZER INC.
$157
Gilead Sciences, Inc.
$145
Genentech USA, Inc.
$94
Novartis Pharmaceuticals Corporation
$64
GlaxoSmithKline, LLC.
$62
ABBVIE INC.
$51
AbbVie Inc.
$44
Pharmacyclics LLC, An AbbVie Company
$40
Blueprint Medicines Corporation
$32
Janssen Biotech, Inc.
$23
CTI BioPharma Corp.
$18
Merck Sharp & Dohme Corporation
$12
Top 3 companies account for 76.2% of all-time payments
Associated products mentioned in payments ›
AYVAKIT · ELIQUIS · ERLEADA · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · KEYTRUDA · KISQALI · Kadcyla · MEKINIST · Perjeta · SCEMBLIX · TECENTRIQ · Trodelvy · VENCLEXTA · VIMSELTINIB · Vonjo · XTANDI · ZEJULA · truFreeze
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (60%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
Hematology & oncology specialists within 10 mi
318
Per 100K population
34.3
County median income
$110,502
Nearest hospital
ADVOCATE GOOD SAMARITAN HOSPITAL
3.4 mi
3.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Chin is a mixed practice specialist, with above-average Medicare volume (top 18% in IL), with speaking/promotional industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Chin experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Chin performed 17,340 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chin receive payments from pharmaceutical companies?
Yes. Dr. Chin received a total of $3,123 from 15 companies across 43 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chin's costs compare to other hematology & oncology specialists in Lisle?
Dr. Chin's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Lisle
Browse hematology & oncology specialists in Lisle ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
Deciphera Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Deciphera Pharmaceuticals Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
STERIS CORPORATION Payments to Doctors
See all physicians who received payments from STERIS CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology